MRI and CT highlight Toshiba releases
Toshiba America Medical Systems will debut two new MRI and CTplatforms at the meeting, according to John Ariatti, vice presidentof marketing. In MRI, the 1.5-tesla Visart employs the graphicaluser interface used in the Tustin, CA, vendor's Flexart
Toshiba America Medical Systems will debut two new MRI and CTplatforms at the meeting, according to John Ariatti, vice presidentof marketing. In MRI, the 1.5-tesla Visart employs the graphicaluser interface used in the Tustin, CA, vendor's Flexart 0.5-teslaMRI platform, introduced in 1993 (SCAN 11/17/93). Visart, to beshown as a work-in-progress, will also use the latest in radio-frequencycoil technology and new magnet and hardware technology, Ariattisaid.
In CT, Toshiba will exhibit a new top-of-the-line scanner, Aspire.The work-in-progress system is a one-second scanner and uses solid-statedetector technology, Ariatti said. Continuous imaging is a work-in-progresshigh-speed CT technique for Aspire that will prove useful in CT-guidedinterventional studies, according to Ariatti. The technique acquiresimages at six frames per second with almost instantaneous reconstruction.Toshiba will also debut XPress/GX, a new spiral CT scanner witha smaller footprint than XPress/SX.
Max 1000 is a new all-purpose digital system for both angiographyand R/F applications. It features a C-arm integrated with a tiltingtabletop.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
